Structures by: Xu X. D.
Total: 7
C52H40Ag2F6N4O10S2,2(CH2Cl2)
C52H40Ag2F6N4O10S2,2(CH2Cl2)
Dalton transactions (Cambridge, England : 2003) (2020) 49, 6 1883-1890
a=10.17488(10)Å b=36.4687(5)Å c=15.21799(16)Å
α=90° β=93.2503(9)° γ=90°
C50H40N4O4
C50H40N4O4
Dalton transactions (Cambridge, England : 2003) (2020) 49, 6 1883-1890
a=12.1001(2)Å b=13.0329(2)Å c=25.4723(4)Å
α=90° β=93.6540(10)° γ=90°
0.5(C108H80Ag8F24N8O32S8),2(H2O)
0.5(C108H80Ag8F24N8O32S8),2(H2O)
Dalton transactions (Cambridge, England : 2003) (2020) 49, 6 1883-1890
a=15.1288(3)Å b=14.0651(3)Å c=29.2057(4)Å
α=90° β=95.672(2)° γ=90°
1M
C31H19NO
Journal of Materials Chemistry C (2019) 7, 44 13786
a=5.0685(13)Å b=12.330(3)Å c=34.435(9)Å
α=90° β=90° γ=90°
3,6-Dibromo-9-(4-tolylsulfonyl)-9H-carbazole
C19H13Br2NO2S
Acta Crystallographica Section E (2006) 62, 5 o1805-o1806
a=8.312(4)Å b=20.573(11)Å c=11.374(6)Å
α=90.00° β=106.867(9)° γ=90.00°
Tetrakis(μ-3,4-dimethoxyphenylacetato)bis[(3,4- dimethoxyphenylacetato)(1,10-phenanthroline)dysprosium(III)]
C84H82Dy2N4O24
Acta Crystallographica Section E (2010) 66, 3 m291
a=12.3287(2)Å b=12.3843(3)Å c=14.6667(3)Å
α=90.9680(10)° β=103.4610(10)° γ=115.5230(10)°
2-Chloro-5-({[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}methyl)pyridine
C15H12ClN3O2S
Acta Crystallographica Section E (2011) 67, 12 o3490
a=12.311(2)Å b=8.1229(15)Å c=29.956(6)Å
α=90.00° β=90.00° γ=90.00°